|By PR Newswire||
|February 8, 2014 04:00 PM EST||
SCOTTSDALE, Ariz., Feb. 8, 2014 /PRNewswire/ -- Applied Biologics LLC, an integrated biotechnology company engaged in the development and commercialization of innovative biologic products derived from the placental tissues, is pleased to announce that Applied Biologics has been awarded a GSA Schedule 20 contract and is now certified to provide goods and services to the Federal government on a national scale.
Acknowledging the growth in federal spending through the General Services Administration (GSA), Applied Biologics has placed their biomedical platform of placental tissue-derived products on the government's electronic ordering system, GSA Advantage!®.
"As a Veteran-owned small business, Applied Biologics has been working closely with numerous VA Medical Centers and Department of Defense (DoD) installations since 2011. This schedule opens up significantly more markets throughout the country and simplifies the purchasing process for the procurement officers," states Edward Britt, President at Applied Biologics. He continues: "Being on the GSA schedule expands our opportunity to reach VA Medical Centers, and DoD installations across the contiguous 48 states, HI, AK and Puerto Rico, as they can now take advantage of our fixed government pricing on our innovative placental tissue-derived products, including FloGraft® and XWRAP® in the management of Chronic Wounds, Sports Medicine, Spine Surgery, OB/GYN, Dental and Ocular Wound Management and a myriad of other medically-related utilization."
Surgeons, physicians and caregivers across the nation find that Applied Biologics products fit organically into their current standard of care by delivering innovative allograft to manage difficult-to-heal wounds, sports injuries, open spine procedures, OB/GYN and urological procedures, and nerve ligament and tendon defects. This newly awarded GSA Schedule Contract, better positions those providers to service the public sector's needs. Applied Biologics continues to provide FloGraft® and XWRAP® to our commercial customers through our vast network of channel partners and distribution network.
About Applied Biologics LLC
Applied Biologics LLC is a global leader in advancing regenerative medicine through the research, translational biotechnology, development and commercialization of placental-tissue derived products, including, but not limited to FloGraft® and XWRAP®. All of our allograft is procured from consenting donors through a scheduled, full-term Caesarean section birth without fetal sacrifice or harm. Amniotic membrane and fluid offer a rich source of native organic cellular components that deserve extensive research to explore their full potential. Immune privilege is a unique characteristic that differentiates this human allograft from other tissue sources. Applied Biologics is focused on optimizing the regenerative potential of this unique allograft. Since 2010, Applied Biologics has been an industry leader in providing innovative amnion-technology for management of soft-tissue defects, orthopedic procedures, sports medicine, chronic wounds, and nerve, ligament and tendon defects. For more information, please visit: www.appliedbiologics.com.
Applied Biologics Forward-looking Statement
This publication may include "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of Applied Biologics' management and are subject to significant risks and uncertainties. Applied Biologics undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Accordingly, all written or oral forward-looking statements attributable to Applied Biologics, LLC are qualified by this caution.
SOURCE Applied Biologics LLC